Call for Symposia

• Symposia submissions will be accepted in English only
• There is no fee for submitting a symposium proposal
• There is a maximum of 2 symposia submissions per person
• All submissions must be a maximum of 500 words
• A table or figure will count as 150 words
• The total word count does not include the title, authors’ details, or references
• CINP recommends using the NbN nomenclature for psychotropics (http://nbn2r.com)

Abstract submissions must be structured with the following:

• Description – 500-word abstract which describes the symposium and the role of each speaker
• Objectives – 100-word learning objectives for the symposia
• References – use Harvard style, where each reference is numbered in order of use

License of copyright and consent to publication

• All authors of the abstract have reviewed the proposal and confirm that all information is correct. The authors accept that the content of this proposal cannot be modified or corrected after final submission, and they are aware that it will be published exactly as submitted
• Submission of the proposal constitutes consent of all authors of the proposal to publication (e.g. conference website, programs, other promotions, journal, etc.)
• All authors of the proposal warrant and represent that they either are the sole owners of, or have all necessary rights to sublicense, all the information and content in the proposal provided to CINP and its conference organizers and that publication of the proposal does not infringe any rights, including, but not limited to, intellectual property rights, of any third parties
• All authors of the proposal grant CINP a royalty-free, perpetual, irrevocable, and nonexclusive license to use, reproduce, publish, translate, distribute, and display the abstract
• All authors of the proposal grant exclusive permission to CINP to record the audio and video portion, if any, of the abstract presentation at the conference and to collect and retain all revenues from all rebroadcasts (including web broadcasts), sales, and publications of such recordings
• CINP reserves the right to remove from any publication any proposal that does not comply with the above
• I confirm that the contact details saved in the CINP proposal submission system are those of the authors or faculty listed in the proposal, who will be notified about the status of the proposal. The submitter of the proposal is responsible for informing the other authors about the status of the proposal. If the proposal is accepted for presentation, it is also the submitting author's responsibility to confirm or decline the proposal’s presentation at the meeting
• If my abstract is a proposal for presentation at the Congress, I agree that it may be published on the Congress website or elsewhere, either prior to or contemporaneously with the Congress and/or in an abstract book that may be distributed electronically.

All submitted proposals will be reviewed by the International Scientific Programme Committee and submitters will be informed whether successful or otherwise in November 2021. Each proposal will be judged on objective evidence on the following criteria:  

• Relevance to CINP
• Standard of English
• Objectivity of statement
• Description of what was done<
• Suitability of methods to aims
• Conclusions confirmed by objective results
• Ethics
• Scientific value
• Potential clinical value
• Originality of work
• Overall impression

The CINP International Scientific Programme Committee welcomes the proposal of symposia that link the latest, and ground-breaking, preclinical developments with the clinical research on a given topic. Through the free and open exchange of ideas, CINP supports a strong focus on new approaches to the development and assessment of CNS pharmaceuticals by researchers working in both academia and industry. Please find below the list of topics:

---

Research

• Clinical
• Preclinical
• Translational
• Others

---

By Disorder

• Addiction Disorders
• Attention Deficit Disorders
• Bipolar Disorders
• Childhood & Adolescent Disorders
• COVID-19
• Dementia
• Depression
• Eating Disorders
• Epilepsy
• Obsessive-Compulsive Disorders
• Pain
• Panic Disorders
• Personality Disorders
• Post-Traumatic Stress Disorders
• Premenstrual Dysphoric Disorder
• chizophrenia
• Sexual Disorders
• Sleep Disorders
• Suicide
• Others

---

By Drug & Methodology

• Animal Models
• Anxiolytics
• Brain Stimulation
• Computational Neuroscience
• Drugs for Depression
• Drugs for Insomnia
• Drugs for Psychosis
• Ethics of Psychopharmacology
• Genetics
• History of Psychopharmacology
• Imaging
• Molecular Neurobiology/Pharmacology
• Drugs for Bipolar Disorders
• Neuropathology/Post-Mortem Studies
• Neurophysiology
• Oriental Medicine
• Pharmacoeconomics
• Pharmacogenetics/Kinetics
• Psychoneuroimmunology
• Transcultural Psychopharmacology
• Others